VX A301
Alternative Names: VX-A301Latest Information Update: 12 Jan 2024
At a glance
- Originator VERAXA Biotech
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 26 Sep 2023 VX A301 is available for licensing as of 26 Sep 2023. https://www.veraxa.com/pipeline (VERAXA Biotech pipeline, September 2023)
- 26 Sep 2023 Early research in Solid tumours in Germany (Parenteral) (VERAXA Biotech pipeline, September 2023)